Complications Archives

August 25, 2022

ASCO 2022: Incidence, Predictors, and Outcomes of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia

CLL patients are at higher risk for several types of cardiac events and have higher rates of in-hospital mortality, regardless of why they were admitted. In addition, this trial was seriously flawed as it did not address what CLL treatments were used. We know certain therapies such as BTKi,

July 27, 2022

Q&A with Dr. Josh Hill on Monkeypox

In this interview, our own Dr. Brian Koffman spoke with Dr. Joshua Hill, an infectious disease specialist at the Fred Hutchinson Cancer Center in Seattle, WA, about monkeypox and the current outbreak. Dr. Hill specializes in the infectious disease care of cancer and other immunocompromised patients.

August 1, 2021

Shingrix Approved in the US for Prevention of Shingles in Immunocompromised Adults

Shingrix is a non-live safe vaccine that is very effective in preventing shingles, the potentially devastating painful reoccurrence of the herpes zoster or chickenpox (varicella) virus (VZV). Keep in mind that you can’t catch shingles from anyone else but yourself. If you have ever had chickenpox (varicella) and 99%

July 16, 2021

Chronic Lymphocytic Leukemia (CLL), Ibrutinib, and Fungal Infections

Sad news. CLL Society just lost a member due to a fatal fungal blood infection that was not identified until the day after he passed as the test was not drawn until the 4th day he’d been in hospital with fever and chills. His wife reached out to ask

December 7, 2019

ASCO 2019: Dr. Koffman’s Pick #8 Second Cancers in Patients Receiving BTK Inhibitors in chronic lymphocytic leukemia (CLL)

Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society of Clinical Oncology Annual Meeting held May 31 – June 4, 2019, Chicago, IL. #8 Second cancer incidence

November 29, 2019

ASCO 2019: CLL Society’s Dr. Koffman’s Pick #10 “Cognitive Function in CLL or chronic lymphocytic leukemia”

Dr. Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society of Clinical Oncology Annual Meeting held May 31 – June 4, 2019 Chicago, IL. #10 Cognitive function in chronic

October 7, 2019

ASH 2018: Dr. Wiestner on the Immune System in CLL (chronic lymphocytic leukemia)

Dr. Adrian Wiestner of the National Institutes of Health has been researching the immune system in chronic lymphocytic leukemia for many years. We know that infections and second cancers are a major concern for all CLL patients as our immune surveillance is compromised leading to more serious infections and

February 13, 2018

Atrial Fibrillation and Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

This is a website about hematology, specifically chronic lymphocytic leukemia, but this article will update research on a significant cardiac condition, atrial fibrillation (AFIB) that is not an uncommon problem for CLL patients and is of particular concern to those on ibrutinib I will focus mostly on the basic

November 14, 2017

Dietary Risks for Heart Disease, Stroke, and Type 2 Diabetes: The Importance in CLL

This is not an article about CLL, but in a way it is. The link between heart disease and cancer is becoming stronger. See http://www.sciencedirect.com/science/article/pii/S0092867410000607 Chronic lymphocytic leukemia (CLL) is likely no exception. There is recent evidence that even precancerous blood clones are associated with atherosclerotic cardiovascular disease in

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Complications

ASCO 2022: Incidence, Predictors, and Outcomes of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia

Q&A with Dr. Josh Hill on Monkeypox

Shingrix Approved in the US for Prevention of Shingles in Immunocompromised Adults

Chronic Lymphocytic Leukemia (CLL), Ibrutinib, and Fungal Infections

ASCO 2019: Dr. Koffman’s Pick #8 Second Cancers in Patients Receiving BTK Inhibitors in chronic lymphocytic leukemia (CLL)

ASCO 2019: CLL Society’s Dr. Koffman’s Pick #10 “Cognitive Function in CLL or chronic lymphocytic leukemia”

ASH 2018: Dr. Wiestner on the Immune System in CLL (chronic lymphocytic leukemia)

Atrial Fibrillation and Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

Dietary Risks for Heart Disease, Stroke, and Type 2 Diabetes: The Importance in CLL

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT